Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study

• Main Authors: Bruno Fautrel (Author), Yoram Bouhnik (Author), Carine Salliot (Author), Franck Carbonnel (Author), Mathurin Fumery (Author), Christophe Bernardeau (Author), Yves Maugars (Author), Mathurin Flamant (Author), Fabienne Coury (Author), Ben Braithwaite (Author), Salima Hateb (Author), Janet Addison (Author), the PERFUSE investigators (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background There is a need for published data on real-world use of SB5, an adalimumab (ADL) biosimilar approved in Europe in 2017, on the basis of evidence from pre-clinical and analytic data as well as phase I and III clinical studies demonstrating equivalent efficacy and comparable pharma...